| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 09/29/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/10/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Entrada Therapeutics Appoints Gina Chapman to its Board of Directors BOSTON, Aug. 10, 2023 -- Entrada Therapeutics, Inc. , a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle -therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. “Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies,” said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. “With a proven track record of advancing therapeutics into the market, Gin..." |
|
| 08/08/2023 |
10-Q/A
| Quarterly Report for the period ended March 31, 2023 [amend] |
| 08/08/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/06/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/06/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/06/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/09/2023 |
8-K
| Other Events Interactive Data |
| 12/19/2022 |
8-K
| Quarterly results |
| 12/08/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
8-K
| Quarterly results |
| 11/01/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|